Logo

Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease

Share this

Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease

Shots:

  • Mestag to receive option fees- milestones- royalties and will deploy its specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets
  • Janssen to get an option to exclusive license to develop and commercialize therapies directed against up to two targets emerges from the collaboration
  • Apart from this collaboration- Mestag will continue to develop its inflammatory disease and cancer programs as it progresses its pipeline of first-in-class therapeutics towards the clinic

  Ref: Mestag Therapeutics | Image: Janssen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions